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Abstract: Mitochondrial dysfunction may play an important role in
abnormal glucose metabolism and systemic inflammation. We aimed
to investigate the relationship between mitochondrial DNA (mtDNA)
copy number and clinical outcomes in peritoneal dialysis (PD)
patients.
We recruited 120 prevalent PD patients and determined mtDNA
copy number by PCR. Primary outcome was all-cause mortality,
whereas secondary outcomes included cardiovascular events, tech-
nical PD failure, and incident malignancy. Cox proportional hazards
analysis determined the independent association of mtDNA copy
number with outcomes.
The mean patient age was 52.3 years; 42.5% were men. The
mean log mtDNA copy number was 3.30 0.50. During a follow-up
period of 35.4 19.3 months, all-cause mortality and secondary
outcomes were observed in 20.0% and 59.2% of patients, respect-
ively. Secondary outcomes were significantly lower in the highest
mtDNA copy number group than in the lower groups. In multiple
Cox analysis, the mtDNA copy number was not associated with all-
cause mortality (lower two vs highest tertile: hazard ratio
[HR]¼ 1.208, 95% confidence interval [CI]¼ 0.477–3.061). How-
ever, the highest tertile group was significantly associated with lower
incidences of secondary outcomes (lower two vs highest tertile: HR
[95% CI]¼ 0.494 [0.277–0.882]) after adjusting for confounding
factors.
The decreased mtDNA copy number was significantly associatedoung Sook Park, M ee, MD,
, MD, PhD, and Tae-Hyun Yoo, MD, PhD
Abbreviations: CI = confidence interval, DMS = dialysis
malnutrition score, ESRD = end-stage renal disease, HDL-C =
high-density lipoprotein cholesterol, HOMA-IR = homeostatic
model assessment-insulin resistance, HR = hazard ratio, hs-CRP =
high-sensitivity C-reactive protein, MIS = malnutrition
inflammation score, mtDNA = mitochondrial DNA, PD =
peritoneal dialysis, ROS = reactive oxygen species, SGA =
Subjective Global Assessment, YUHS = Yonsei University
Health System.
INTRODUCTION
M ortality risks for end-stage renal disease (ESRD) patientsare known to be higher than that for patients with other
grave comorbidities such as cancer, stroke, or acute myocardial
infarction.1 Extremely high mortality rates in ESRD patient are
not fully explicable by traditional risk factors such as age,
diabetes mellitus, smoking, hypertension, dyslipidemia,
obesity, and family history.2 Therefore, recent investigations
have attempted to explain these elevated mortality risks by
evaluating the impact of so-called nontraditional risk factors
such as uremia,3 insulin resistance,4 inflammation,5 and oxi-
dative stress.6 Especially in patients maintaining PD, chronic
exposure to high-glucose-containing peritoneal dialysis (PD)
solution can induce many hazardous clinical outcomes includ-
ing malnutrition, hypertriglyceridemia, poor glycemic control,
and incident diabetes7 that are considered to be signs of
mitochondrial injury.8
Mitochondria are ubiquitous organelles of eukaryotic sys-
tems that are essential for supplying cellular energy by the
aerobic production of adenosine triphosphate via oxidative
phosphorylation.9 Additionally, mitochondria are involved in
numerous cellular tasks including regulation of metabolism,
induction of reactive oxygen species (ROS) signaling, and
apoptosis.9 Mitochondrial damage and consequent dysfunction
are implicated in various cell metabolism-related human dis-
eases such as cancer, neurodegenerative diseases, and dia-
betes.10–12 In particular, mitochondrial dysfunction in
subjects who are older or have chronic illnesses is related to
deletion of mitochondrial genes rather than mutations in mito-
chondrial DNA (mtDNA).13 Mitochondria are highly suscept-
ible to oxidative stress and are a target of ROS as well producers
of it. Recent data revealed that the mtDNA copy number reflects
the level of mitochondrial biogenesis as well as the amount of
mtDNA. The lowmtDNA copy number is associated with aging
and various human diseases, including diabetes, cardiomyopa-
thy, and cancer.14
Recent studies reported that the mtDNA copy number was
d with clinical outcome in dialysis
mtDNA copy number correlates with
ess and higher mortality rates in patients
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undergoing dialysis. In a uremic rat model, the mtDNA copy
number was also significantly decreased compared to control
rats, and was associated with decreased renal function.17 Such
clinical and experimental studies suggest that the mtDNA copy
number could be a potential biomarker for clinical outcomes in
dialysis patients as well as the general population. Therefore, we
aimed to test this hypothesis by investigating the association
between the mtDNA copy number and clinical outcomes in
patients undergoing PD.
METHODS
Ethics Statement
The study was carried out in accordance with the Declara-
tion of Helsinki and approved by the Institutional Review Board
of Yonsei University Health System (YUHS) Clinical Trial
Center. We obtained informed written consent from all
participants involved.
Subjects
The study population was comprised of participants in a
prospective cohort that included prevalent PD patients at the
YUHS. The study was designed to investigate cardiovascular
risk and mortality in PD patients.18 All consecutive ESRD
patients >18 years of age who underwent PD for >3 months
at YUHS were initially screened for enrollment between Feb-
ruary 2010 and Dec 2011. Patients were excluded if they had
histories of overt infection or malignancy, or had another
chronic inflammatory disease such as rheumatoid arthritis or
systemic lupus erythematosus, within 3 months of enrollment.
Patients with a history of kidney transplantation, hemodialysis
for >3 months before PD, or cardiovascular disease within the
prior 3 months were also excluded. Ultimately, 120 prevalent
PD patients were included (Figure 1).
A senior nursing clinician obtained demographic data via
interviews. Demographic and clinical data recorded at study
entry included age, sex, and PD duration. Weight, height, and
biochemical data were measured at study enrollment. The body
Yoon et almass index was calculated as weight/height (kg/m2). Diabetes
mellitus and hypertension were defined as described pre-
viously.19,20
FIGURE 1. Flow diagram of the study. HD¼hemodialysis,
KT¼ kidney transplantation, PD¼peritoneal dialysis, RA¼
rheumatoid arthritis, SLE¼ systemic lupus erythematosus.
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The blood samples were obtained from study subjects after
overnight fasting for 12 h, and plasma was extracted and frozen
at 708C before experiment. The laboratory values including
hemoglobin, albumin, lipid profiles, calcium, phosphorus, and
high-sensitivity C-reactive protein (hs-CRP) were measured at
baseline. Fasting plasma glucose was determined by the glucose
oxidase method. Lipid profiles including total cholesterol, high-
density lipoprotein cholesterol (HDL-C), low-density lipopro-
tein cholesterol, and triglyceride were measured by enzymatic
colorimetry using an autoanalyser (Hitachi 7150, Hitachi Ltd,
Tokyo, Japan), and hs-CRP was determined by a latex-enhanced
immunonephelometric method using a BNII analyzer (Dade
Behring, Newark, DE). Insulin resistance was assessed by using
the homeostatic model assessment-insulin resistance (HOMA-
IR) equation as follows: HOMA-IR¼ (fasting insulin in micro-
unit per liter fasting plasma glucose in millimoles per liter/
22.5).21 Plasma adiponectin (B-Bridge International, Sunny-
vale, CA) and leptin (R&D Systems, Minneapolis, MN) were
measured using enzyme-linked immunosorbent assays.
Definition of Malnutrition Inflammation Score
The malnutrition inflammation score (MIS) was calculated
as described previously.22 The Subjective Global Assessment
(SGA) of nutritional state was assessed by history and physical
examination.23 The Dialysis Malnutrition Score (DMS),24
which incorporates 7 conventional SGA components (weight
change, dietary intake, gastrointestinal symptoms, functional
capacity, comorbidity, subcutaneous fat, and signs of muscle
wasting), was included. To attempt to produce a more compre-
hensive and quantitative scoring system, 3 new items were
added to the DMS criteria: body mass index, serum albumin
levels, and total iron-binding capacity. The MIS has 10 com-
ponents ranging from 0 (normal) to 30 (severely malnourished);
a higher score reflects a more severe degree of malnutrition and
inflammation.22
Quantification of mtDNA Copy Number
Nucleic acids were extracted from white blood cells using a
previously described method.25 An assay based on real-time
quantitative PCR was used for the mtDNA copy number quanti-
fication using SYBR green as a fluorescent dye (Invitrogen,
Buenos Aires, Argentina). Quantification of mtDNA copy num-
ber was performed as described previously.8,26 Briefly, DNAwas
extracted from a 1mL peripheral whole blood sample using the
QIAampTissueKit 250 (Qiagen Inc, Valencia, CA), according to
the manufacturer’s instructions. The mtDNA copy number was
expressed as a relative ratio between quantitative PCR measured
mtDNA gene copy number and a simultaneous measurement of
nuclear DNA copy number. To assess the mtDNA gene copy
number, a 120-bp-long mtDNA fragment within the mitochon-
drialND1 genewas amplified. TheND1 forward primer usedwas
50CCCTAAAACCCGCCACATCT30, and reverse primer was
50GAGCGATGGTGAGAGCTAAGGT30. The lipoprotein lipase
genewas amplified to assess the nuclear DNAcopy number using
the primers forward 50CGAGTCGTCTTTCTCCTGATGAT0 and
reverse 50TTCTGGATTCCAATGCTTCGA0. Real-time PCR
was conducted in a total of 20-mL volume, 10mL of SYBR
GreenMasterMix (AppliedBiosystems), 5mLofDNA, and5pM
each of primers. The PCR cycles were conditioned by initial
Medicine  Volume 95, Number 7, February 2016heating at 958C for 9minutes; 35 cycles of denaturation at 94.58C
for 30 s, annealing at 608C for 30 s, and extension at 728C for
1minute; and final extension at 728C for 7minutes. Triplicate
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analysis was performed in each sample. After the reaction
of PCR, the temperature was increased to 958C at a rate
of 28C/minute to make a melting curve.27 The ratio of
mtDNA/nuclear DNA was calculated as 2DCT, where DCT
is CTLDL  CTND1. Intra-assay and inter-assay coefficients of
variation of mtDNA copy number were 4.7% (range 1.8–6.7)
and 5.9% (range 3.7–9.1), respectively.
Assessment of Dialysis Adequacy and Lean Body
Mass Using Creatinine Kinetics
Urea kinetics studies were conducted based on a 24-hour
collection of dialysate and urine at the time of study enrollment.
Kt/Vurea was determined from the total loss of urea nitrogen in
spent dialysate using PD Adequest 2.0 for Windows software
(Baxter Healthcare, Deerfield, IL). Lean body mass was esti-
mated by creatinine kinetics, and the percentage lean body mass
was calculated as lean body mass normalized to dry weight.
Follow-Up and Endpoints
Patients were seen for follow-up at 3-month intervals
through July 1, 2015. All deaths and hospitalizations were
documented in a database from which all events were retrieved.
Primary outcome was defined as all-cause mortality. Secondary
outcomes were defined as major cardiovascular events, PD
failure, or incident malignancy. Cardiovascular events were
defined as death or hospitalization from an acute coronary
syndrome and stable angina requiring coronary revasculari-
zation or coronary bypass surgery. Cerebrovascular events
and peripheral vascular disease were also deemed major car-
diovascular events. Cerebrovascular events were defined as
hospitalization or visit to the emergency department for a
transient ischemic attack, ischemic stroke, or carotid endarter-
ectomy. Peripheral vascular disease was defined as ischemic
limb loss and/or ulceration or peripheral revascularization
procedure. PD failure referred to a technical failure of PD.
Incident malignancy was defined as malignancy that was con-
firmed by pathologic or radiological diagnosis regardless of
primary origin or stage. Subjects lost to follow-up and kidney
transplantation recipients were censored in the final analysis.
Statistical Analysis
The means and standard deviations were used to indicate
continuous variables, and frequencies and percentages were
estimated for categorical data. The Kolmogorov–Smirnov test
was performed to confirm the normality of distribution. The
trichotomized mtDNA copy number groups were compared by
ANOVA for continuous variables and the trend test or Fisher’s
exact test for categorical variables. To test the significant factors
associated with mtDNA copy number, univariate and multi-
variate linear regression analyses were conducted. Regarding
the distribution of variables, triglyceride, intact-parathyroid
hormone, ferritin, leptin, leptin–adiponectin ratio, hs-CRP,
HOMA-IR, and mtDNA copy number were transformed to
natural logarithmic values for linear regression analysis. Vari-
ables that had P values <0.1 on univariate linear regression
analysis were included in multivariate linear regression
analysis. Comparisons between the highest mtDNA copy num-
ber tertile and the lower two mtDNA copy number tertiles were
performed by Kaplan–Meier analysis and a log-rank test. The
independent predictive role of mtDNA copy number in clinical
Medicine  Volume 95, Number 7, February 2016outcomes was determined by Cox proportional hazard analysis,
which included significant variables in the comparison of base-
line characteristics and linear regression analysis. Statistical
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.analysis was performed with SPSS for Windows version 20.0
(IBM SPSS Inc, Chicago, IL). P values of <0.05 were
considered significant.
RESULTS
Baseline Characteristics According to the mtDNA
Copy Number
The baseline characteristics are shown in Table 1. The
mean age of the study population was 52.3 12.0 years; 51
(42.5%) patients were men. The mean duration of PD was
88.5 49.3 months, and the mean log mtDNA copy number
was 3.30 0.50. Patients were divided into 3 groups according
to their mtDNA copy number. Previous history of coronary
artery disease (12.5% vs 7.5% vs 0%, P¼ 0.04) and MIS
(6.3 2.2 vs 6.8 1.7 vs 3.9 1.4 respectively, P< 0.001)
were significantly lower in the highest mtDNA copy number
group compared to the lower and middle groups, respectively.
Composites of Secondary Outcome Were
Significantly Lower in the Highest mtDNA
Copy Number Group
During a mean follow-up duration of 35.4 19.3 months,
all-cause mortality and secondary outcomes were observed in
24 (20.0%) and 71 (59.2%) patients, respectively (Table 2).
There were no significant differences in all-cause mortality in
any of the trichotomized mtDNA copy number groups (25.0%
vs 15.0% vs 20.0% respectively, P¼ 0.68). Meanwhile, com-
posites of secondary outcome were significantly lower in the
highest mtDNA copy number group compared to the lower or
middle mtDNA copy number groups (75.0% vs 62.5% vs 40.0%
respectively, P¼ 0.002). Among secondary outcomes, PD fail-
ure (55.0% vs 55.0% vs 27.5% respectively, P¼ 0.02) and
incident malignancy (30.0% vs 20.0% vs 10.0% respectively,
P¼ 0.04) were significantly lower in the highest tertile mtDNA
copy number group. As for incident malignancies, urogenital
cancer was the most frequent (8 renal cell carcinoma, 2 ureter
cancers, and 1 bladder cancer), followed by gastrointestinal
cancer (2 stomach cancers, 2 colorectal cancers, and 1 hepa-
tocellular carcinoma), breast and gynecologic cancers (ovarian,
cervical, and endometrial cancer, respectively), and thyroid
cancer. There was no significant difference in cardiovascular
events among the groups (15.0% vs 17.5% vs 7.5% respect-
ively, P¼ 0.42).
Association of Clinical and Biochemical Variables
With mtDNA Copy Number
Linear regression analyses were performed to investigate
the association between clinical/biochemical variables and log
mtDNA copy number. On univariate analysis, previous coron-
ary artery disease (b¼0.622, P¼ 0.007), white blood cell
(per 1000 cells/mL, b¼0.065, P¼ 0.04), fasting plasma glu-
cose (b¼0.004, P¼ 0.02), log hs-CRP (b¼0.082,
P¼ 0.03), log HOMA-IR (b¼0.130, P¼ 0.03), and MIS
(b¼0.088, P¼ 0.02) were negatively correlated with
mtDNA copy number, whereas adiponectin (b¼ 0.016,
P¼ 0.03) was positively correlated (data not shown). Multi-
variate linear regression analysis was also performed to clarify
the independent association of variables with log mtDNA copy
Mitochondrial DNA and Peritoneal Dialysis Outcomenumber (Table 3). The analysis indicated that log mtDNA copy
number was independently associated with log hs-CRP
(b¼0.085, P¼ 0.04) and MIS (b¼0.072, P¼ 0.03).
www.md-journal.com | 3
TABLE 1. Baseline Characteristics of Subjects According to the mtDNA Copy Number
Variables Group 1 (n¼ 40) Group 2 (n¼ 40) Group 3 (n¼ 40) P
Age (years) 51.6 12.0 54.1 12.9 51.1 11.0 0.48
Sex (male, %) 17 (42.5) 16 (40.0) 18 (45.0) 0.82
PD duration (months) 93.2 49.9 87.4 55.3 84.8 42.9 0.74
Kt/V 2.0 0.3 2.0 0.2 1.9 0.3 0.13
Anuria (%) 35 (87.5) 28 (70.0) 36 (90.0) 0.70
Diabetes mellitus (%) 3 (7.5) 3 (7.5) 4 (10.0) 0.84

Hypertension (%) 29 (72.5) 30 (75.0) 31 (77.5) 0.61
Previous CAD (%) 5 (12.5) 3 (7.5) 0 (0) 0.04

Previous stroke (%) 4 (10.0) 1 (2.5) 1 (2.5) 0.20

Body mass index (kg/m2) 24.0 3.9 23.3 3.4 23.8 3.5 0.67
Lean body mass (%) 72.2 10.2 72.4 10.9 75.2 11.7 0.40
SBP (mm Hg) 140.6 20.9 143.0 18.1 148.2 19.9 0.23
DBP (mm Hg) 84.4 10.8 85.5 9.9 85.5 8.2 0.86
WBC (1000 cells/mL) 6.74 1.72 6.30 1.94 6.30 1.90 0.48
Hemoglobin (g/dL) 10.5 1.7 10.2 1.1 10.4 1.5 0.76
FPG (mg/dL) 101.9 38.1 95.9 11.6 90.0 15.4 0.10
HCO3 (mmol/L) 26.4 3.0 25.8 2.3 26.0 2.9 0.58
Total cholesterol (mg/dL) 195.0 37.0 185.9 39.1 181.2 43.0 0.29
Triglyceride (mg/dL) 178.3 115.2 155.9 150.6 138.1 69.3 0.31
HDL-C (mg/dL) 42.4 11.6 46.9 14.4 44.7 12.3 0.31
LDL-C (mg/dL) 119.2 39.0 107.8 36.4 108.9 38.2 0.35
Serum albumin (g/dL) 3.5 0.4 3.4 0.3 3.6 0.4 0.07
CaP product (mg2/dL2) 46.9 12.2 45.1 10.6 50.2 9.3 0.11
Intact PTH (pg/mL) 182 (64.7–380.2) 151.0 (71.5–307.5) 248.1 (89.6–390.0) 0.42
Uric acid (mg/dL) 7.0 1.4 6.5 0.9 6.7 1.1 0.21
Iron (mg/dL) 73.5 27.6 67.0 24.9 68.0 31.7 0.54
Ferritin (ng/mL) 323.6 (279.1–550.6) 310.1 (195.2–474.1) 406.3 (268.6–480.3) 0.31
Leptin (ng/dL) 14.6 (4.1–26.3) 12.9 (5.3–50.6) 8.9 (2.7–16.8) 0.13
Adiponectin (ng/dL) 17.1 8.1 19.1 7.7 20.3 6.2 0.16
Leptin–adiponectin ratio 0.89 (0.19–3.31) 0.58 (0.27–3.27) 0.45 (0.12–1.05) 0.11
hs-CRP (mg/L) 2.08 (0.51–5.17) 1.79 (0.44–4.97) 0.93 (0.23–3.11) 0.12
HOMA-IR 4.26 (2.64–10.44) 4.08 (2.95–8.35) 3.66 (2.08–6.33) 0.48
MIS 6.3 2.2 6.8 1.7 3.9 1.4 <0.001
mtDNA copy number y 2.86 0.16 3.24 0.10 3.73 0.31 <0.001
Lowest, middle, and highest mtDNA copy number groups are expressed as group 1, 2, and 3, respectively.
Fisher’s exact test.
y log transformed.Ca¼ calcium, CAD¼ coronary artery disease, DBP¼ diastolic blood pressure, FPG¼ fasting plasma glucose, HDL-C¼ high-
density lipoprotein cholesterol, HOMA-IR¼ homeostatic model assessment-insulin resistance, hs-CRP¼ high-sensitivity C-reactive protein, LDL-
C¼ low-density lipoprotein cholesterol, MIS¼malnutrition inflammation score, mtDNA¼mitochondrial DNA, P¼ phosphate, PD¼ peritoneal
BC
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Risk Factor for Adverse Clinical Outcomes in
PD Patients
Multivariate Cox proportional hazard analysis was per-
formed to investigate the prognostic role of mtDNA copy
number in all-cause mortality, cardiovascular events, PD fail-
ures, and incident malignancies in PD patients (Table 4).
The mtDNA copy number was not significantly associated with
all-cause mortality (lower two groups vs highest: hazard ratio
[HR]¼ 1.21, confidence interval [CI]¼ 0.477–3.061, P¼ 0.69)
after adjustment for age, sex, PD duration, previous history of
coronary artery disease, serum albumin, hs-CRP, and MIS.
However, the composites of secondary outcome were signifi-
dialysis, PTH¼ parathyroid hormone, SBP¼ systolic blood pressure, Wcantly decreased in the highest mtDNA copy number group
compared to the lower two mtDNA copy number groups after
adjustment for the same confounding factors (lower two groups
4 | www.md-journal.comvs highest: HR [CI]¼ 0.494 [0.277–0.882], P¼ 0.02). Kaplan–
Meier plots showed that all-cause mortality was not signifi-
cantly different between the mtDNA copy number groups (log-
rank test; P¼ 0.89; Figure 2). However, the composites of
secondary outcomes were significantly lower in the highest
mtDNA copy number group compared to the lower two mtDNA
copy number groups (P¼ 0.03). Moreover, event rates of PD
failure (P¼ 0.049) and incident malignancies (P¼ 0.04) were
significantly lower in the highest mtDNA copy number group
compared to the lower two groups (Figure 3).
DISCUSSION
Our data showed that the mtDNA copy number is signifi-
¼white blood cell.cantly associated with inflammatory or nutritional markers
such as hs-CRP and MIS in PD patients. Furthermore, the
mtDNA copy number was independently associated with
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 2. Clinical Outcome According to mtDNA Copy Number
Variables Total Group 1 Group 2 Group 3 P
All-cause mortality (%) 24 (20.0) 10 (25.0) 6 (15.0) 8 (20.0) 0.68
Secondary outcome (%) 71 (59.2) 30 (75.0) 25 (62.5) 16 (40.0) 0.002
CV event (%) 16 (13.3) 6 (15.0) 7 (17.5) 3 (7.5) 0.42
PD failure (%) 55 (45.8) 22 (55.0) 22 (55.0) 11 (27.5) 0.02
Malignancies (%) 24 (20.0) 12 (30.0) 8 (20.0) 4 (10.0) 0.04
Urogenital cancer (%) 11 (9.2) 5 (12.5) 3 (7.5) 3 (7.5)
Gastrointestinal cancer (%) 5 (4.2) 3 (7.5) 1 (2.5) 1 (2.5)
Breast cancer (%) 3 (2.5) 2 (5.0) 1 (2.5) 0
Gynecologic cancer (%) 3 (2.5) 1 (2.5) 2 (5.0) 0
Thyroid cancer (%) 2 (1.7) 1 (2.5) 1 (2.5) 0
Lowest, middle, and highest mtDNA copy number groups are expressed as group 1, 2, and 3, respectively.
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Medicine  Volume 95, Number 7, February 2016 Mitochondrial DNA and Peritoneal Dialysis Outcomeadverse clinical outcomes, including PD failure and incident
malignancy.
Many studies revealed that mitochondria have an essential
role in the pathophysiology of diverse diseases and aging.13,16,28
Initially, genetic mutations in mitochondria had been observed
in rare inherited disorders; however, recent studies reported that
mitochondrial dysfunction and low mtDNA copy number have
been implicated in the pathogenesis of chronic metabolic ill-
nesses such as diabetes11 and dementia.29 Although the mech-
anisms surrounding decreased mtDNA copy number on several
diseases are still not fully understood, several studies point to
oxidative stress, inflammation, and malnutrition as highly
probable factors.30–32 As a modest increase in oxidative stress
and chronic inflammation was frequently observed in chronic
kidney disease patients, including those on dialysis,6 chronic
exposure to uremia has also been proposed to play a role in
Urogenital cancers include 8 renal cancers, 2 ureter cancers, and 1 blad
cancers, and 1 hepatocellular carcinoma; gynecologic cancers include o
CV¼ cardiovascular, mtDNA¼mitochondrial DNA, PD¼ peritoneainducing mitochondrial deficiency and consequent dysfunction.
In addition, protein-energy wasting is commonly observed and
closely linked to poor clinical outcomes in ESRD patients.33
TABLE 3. Multivariate Linear Regression Analysis for the
Association of mtDNA Copy Number With Clinical and Bio-
chemical Variables
Variable Multivariate
b P
Previous coronary artery disease 0.640 0.13
White blood cell (per 1000 cells/mL) 0.011 0.78
Fasting plasma glucose (per 1 mg/dL) 0.003 0.39
Triglyceride (per 1 log)
 0.086 0.48
Uric acid (per 1 mg/dL) 0.089 0.08
Adiponectin (per 1 ng/dL) 0.010 0.25
hs-CRP (per 1 log)
 0.089 0.04
HOMA-IR (per 1 log)
 0.085 0.28
Malnutrition inflammation score (per 1 point) 0.072 0.03

log transformed; mtDNA copy number was also log transformed.
HDL-C¼ high-density lipoprotein cholesterol, HOMA-IR¼
homeostatic model assessment-insulin resistance, hs-CRP¼ high-
sensitivity C-reactive protein, LDL-C¼ low-density lipoprotein
cholesterol, mtDNA¼mitochondrial DNA.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.Especially, patients treated with PD are highly vulnerable to
malnutrition caused by inadequate protein intake combined
with persistent protein loss through the peritoneal membrane.34
Moreover, chronic inflammation and pro-inflammatory cyto-
kines cause malnutrition by increasing protein hydrolysis.35 The
present study also demonstrated that the mtDNA copy number
is closely linked to hs-CRP as an inflammatory marker and to
MIS as a nutritional marker. These findings suggest that mito-
chondrial abnormalities could be potential pathophysiologic
mechanisms inducing malnutrition-inflammation-cachexia syn-
drome in PD patients.
In the present study, the low mtDNA copy number was
associated with a higher technical failure rate in prevalent PD
patients. It is unclear why a low mtDNA copy number results in
technical failure. PD peritonitis is the main cause of catheter
removal in PD patients,36 and recurrent or refractory PD
peritonitis was the single most common reason for transfer to
hemodialysis in the study subjects. Moreover, the number of
cancer; gastrointestinal cancers include 2 stomach cancers, 2 colorectal
ian, cervical, and endometrial cancer.
lysis.peritonitis-related technical failures was greater in the lowe
two mtDNA copy number groups compared to the highes
mtDNA copy number group (68.2% vs 54.6%, respectively)
TABLE 4. Multivariate Cox Proportional Hazard Regression
Analysis for the Association of mtDNA Copy Number With
Clinical Outcomes
Highest mtDNA Copy Number
HR (95% CI) P
All-cause mortality 1.208 (0.477–3.061) 0.69
Secondary outcomes 0.494 (0.277–0.882) 0.02
Cardiovascular events 0.376 (0.105–1.351) 0.13
Peritoneal dialysis failure 0.478 (0.239–0.957) 0.04
Incident malignancy 0.483 (0.158–1.482) 0.20
All results adjusted for age, sex, peritoneal dialysis duration, previou
history of coronary artery disease, serum albumin, high-sensitivity C
reactive protein, and malnutrition inflammation score.
HR was calculated using the lower two mtDNA copy number group
as a reference.
CI¼ confidence interval, HR¼ hazard ratio, mtDNA¼ mitochon
drial DNA.
www.md-journal.com | 5r
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FIGURE 2. Kaplan–Meier plots for all-causemortality-free survival
between the lower two and the highest mtDNA copy number
Yoon et alRecent reports demonstrated that mitochondria participate in
innate immunity and are involved in immune response to
bacterial and viral infection.37 It is assumed that host immunity
is modulated by mitochondria, and mitochondrial dysfunction
increases susceptibility to bacterial or viral infection. On the
other hand, risk factors related to PD peritonitis include diabetes
and hypoalbuminemia as markers for malnutrition and residual
renal function.38,39 As mentioned above, the mtDNA copy
number is closely associated with MIS. We surmised that
malnutrition and susceptibility to infection are related to the
low mtDNA copy number and might increase the risk of PD
peritonitis in our subjects. Therefore, the increased peritonitis
rate may partially account for a higher technical failure rate in
the low mtDNA copy number groups.
Although the present study showed that the low mtDNA
copy number as an independent predictor of adverse clinical
outcomes in PD patients, evidence to suggest that the mtDNA
copy number is a direct indicator of adverse clinical outcomes in
PD remains weak. However, several previous studies showed
tertile groups. Lowest, middle, and highest mtDNA copy number
groups are expressed as group 1, 2, and 3, respectively.
mtDNA¼mitochondrial DNA.that a low mtDNA copy number is predictive of all-cause
mortality or incident cardiovascular events in highly morbid
populations such as those with heart failure and ESRD.16,40
FIGURE 3. Kaplan–Meier plots for composites of secondary outcomes
number tertile groups. Composites of secondary outcomes include
malignancies. Lowest, middle, and highest mtDNA copy number gro
Meier plots for peritoneal dialysis failure-free survival between the lowe
middle, and highest mtDNA copy number groups are expressed as g
incident malignancy-free survival between the lower two and the hi
highest mtDNA copy number groups are expressed as group 1, 2, a
6 | www.md-journal.comFurthermore, the mtDNA copy number is closely related to the
nontraditional risk factor such as inflammation.41 It is well
known that oxidative stress is closely related to chronic inflam-
mation and that mitochondria are highly susceptible to oxidative
stress. We speculated that the low mtDNA copy number, which
is a consequence of chronic inflammation and oxidative stress,
was associated with poor clinical outcomes in the present study.
The mtDNA copy number and mitochondrial dysfunction
have also been reported to be closely related to the development
of malignancy in the general population.42 Furthermore, dialy-
sis patients have a higher risk of developing cancer.43 Although
mitochondrial dysfunction may be prevalent in ESRD patients,
the association between cancer risk and mitochondrial dysfunc-
tion is still elusive. The relationship between the low mtDNA
copy number and risk of malignancy in this study suggests that
the low mtDNA copy number and consequent mitochondrial
dysfunction could increase the risks of developing malignancies
in dialysis patients.
There are several limitations to our study. First, the study
subjects were relatively small in number and were undergoing
prevalent PD at a single center, possibly causing selection bias.
Additionally, the significant differences found in adverse
clinical outcomes were observed when comparing the highest
tertile to the lowest or lower two mtDNA copy number tertiles
and not in a stepwise manner (Supplementary Figures 1 and 2,
http://links.lww.com/MD/A732). These results may be due to
the small population size. Moreover, there exists the possibility
that the threshold mtDNA copy number control, which was
proposed by Laura et al, might partly influence these results.14
There is a pathologic threshold level ofmtDNAcopy number that
needs to be maintained for healthy homeostasis, and the reduced
mtDNA copy number below the threshold in PD patients may
lead to various adverse clinical outcomes. However, the exact
triggering mechanism is still obscure; therefore, larger scale
studies are required to confirm our findings. The absence of
subsequent mtDNA copy number measurements during follow-
upwas another limitation in this study. ThemtDNAcopy number
of the study population may have changed during the follow-up
period, and obtaining average levels over time would have added
reliability. Although we did not check mtDNA copy number
serially, we only enrolled patients on PD who were relatively
stable. As the study was observational rather than interventional,
Medicine  Volume 95, Number 7, February 2016and single measurements of the mtDNA copy number at baseline
were used for analysis, the causal relationship between mtDNA
copy number and clinical outcomes has not been clarified.
-free survival between the lower two and the highest mtDNA copy
d cardiovascular events, peritoneal dialysis failure, and incident
ups are expressed as group 1, 2, and 3, respectively. (B) Kaplan–
r two and the highest mtDNA copy number tertile group. Lowest,
roup 1, 2, and 3, respectively. (C) Kaplan–Meier plots comparing
ghest mtDNA copy number tertile groups. Lowest, middle, and
nd 3, respectively. mtDNA¼mitochondrial DNA.
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In conclusion, we demonstrated that the low mtDNA
copy number is significantly associated with adverse clinical
outcomes in maintenance PD patients. It is also significantly
associated with markers of systemic inflammation and mal-
Medicine  Volume 95, Number 7, February 2016nutrition. These findings suggest that the mtDNA copy
number could be helpful in predicting clinical outcomes in
PD patients.
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